| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 40,996 | 35,480 | ||
| Current portion of investments in u.s. treasury securities | 81,768 | 97,413 | ||
| Prepaid expenses and other current assets | 5,029 | 7,169 | ||
| Total current assets | 127,793 | 140,062 | ||
| Non-current portion of investments in u.s. treasury securities | 0 | 19,613 | ||
| Long-term investment | 3,390 | 3,390 | ||
| Restricted cash | 3,248 | 3,248 | ||
| Total property and equipment | 1,898 | - | ||
| Less accumulated depreciation | 668 | - | ||
| Property and equipment, net | 1,230 | 1,115 | ||
| Lease right-of-use assets - finance | 1,220 | 1,300 | ||
| Lease right-of-use assets - operating | 6,963 | 7,340 | ||
| Total assets | 143,844 | 176,068 | ||
| Accounts payable | 4,656 | 20,025 | ||
| Accrued expenses and other current liabilities | 9,900 | 8,912 | ||
| Current portion of lease liabilities - finance | 568 | 520 | ||
| Current portion of lease liabilities - operating | 2,147 | 2,136 | ||
| Total current liabilities | 17,271 | 31,593 | ||
| Non-current portion of lease liabilities - finance | 454 | 577 | ||
| Non-current portion of lease liabilities - operating | 5,288 | 5,680 | ||
| Total liabilities | 23,013 | 37,850 | ||
| Common stock, 0.0001 par value, 500,000,000 shares authorized as of september 30, 2025 54,935,477 shares issued and 54,934,275 shares outstanding as of september 30, 2025 500,000,000 shares authorized as of december 31, 2024 33,079,209 shares issued and 33,071,261 shares outstanding as of december 31, 2024 | 5 | 5 | ||
| Treasury stock, at cost, 3,827 common shares as of september 30, 2025 and as of december 31, 2024 | 17 | 17 | ||
| Additional paid-in capital | 479,969 | 477,175 | ||
| Accumulated other comprehensive gain (loss) | 89 | -13 | ||
| Accumulated deficit | -359,215 | -338,932 | ||
| Total stockholders' equity | 120,831 | 138,218 | ||
| Total liabilities and stockholders' equity | 143,844 | 176,068 | ||
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)